Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome
- 21 November 2007
- journal article
- review article
- Published by Elsevier in Physiology & Behavior
- Vol. 93 (4-5) , 671-686
- https://doi.org/10.1016/j.physbeh.2007.11.012
Abstract
No abstract availableKeywords
This publication has 118 references indexed in Scilit:
- Multiple pathways involved in the biosynthesis of anandamideNeuropharmacology, 2007
- [18F]MK-9470, a positron emission tomography (PET) tracer forin vivohuman PET brain imaging of the cannabinoid-1 receptorProceedings of the National Academy of Sciences, 2007
- Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversionsPhysiology & Behavior, 2007
- The Hormonal Control of Food IntakeCell, 2007
- Endothelium‐dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2‐arachidonoylglycerolBritish Journal of Pharmacology, 2007
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Activation of G-proteins in brain by endogenous and exogenous cannabinoidsThe AAPS Journal, 2006
- Natural cannabinoids: Templates for drug discoveryLife Sciences, 2005
- Cannabinoid signallingPublished by Elsevier ,2005